bims-rebome 2025-12-07 papers

Discov Oncol. 2025 Dec 02.

Global trends in breast cancer bone metastasis research (2009-2024): a bibliometric and visual analysis of hotspots and future directions.

Zhichao Wang, Yin Zuo, Xinyu Chen, Yongchun Pan, Zhicheng He, Songrui Xu, Yuan Li, Pengcui Li, Xiaochun Wei, Yunfeng Xu, Yi Feng, Zhi Tian.

BACKGROUND: Breast cancer bone metastasis (BCBM) is a prevalent complication with significant impact on patient survival and quality of life. Understanding the research landscape is crucial for guiding future studies. This bibliometric analysis aims to visualize and analyze global research trends in BCBM from 2009 to 2024.
METHODS: The Web of Science Core Collection (WoSCC) database was searched for relevant literature on BCBM published between 2009 and 2024. CiteSpace and VOSviewer software were utilized to perform visual mapping and analyze contributors, countries/regions, journals, keywords, research hotspots, and frontiers.
RESULTS: A total of 210 articles met the inclusion criteria. The annual publication output showed a general upward trend. Ottewell, Penelope D published the most papers (12). China (74 articles, 35.24%) and the United States (71 articles, 33.81%) were the leading contributing countries, with no significant difference in output volume (χ² = 0.12, P = 0.729). Cancers was the most prolific journal. Keyword clustering analysis revealed central themes including "breast cancer", "bone metastasis", "expression", "cell", and "growth". Burst keyword detection indicated current research hotspots focus on the tumor-bone microenvironment (BMME) and tumor cell-bone cell interactions. Analysis of co-cited references highlighted foundational research on metastatic mechanisms.
CONCLUSION: From 2009 to the present, many studies have been conducted in the field of breast cancer bone metastasis, and various results have been achieved. Currently, academics are more inclined to explore the specific mechanism from the perspective of molecular biology, and use it to develop corresponding targeted drugs for clinical practice, future research should prioritize microenvironmental crosstalk and AI-driven predictive models to accelerate therapeutic breakthroughs.

Keywords: Bibliometrics; Bone metastasis; Bone metastasis microenvironment (BMME); Breast cancer; Molecular mechanisms

DOI: https://doi.org/10.1007/s12672-025-03852-x

Cancer Radiother. 2025 Nov 28. pii: S1278-3218(25)00185-4. [Epub ahead of print]29(7-8): 104769

Radiotherapy of bone metastases: 2025 update.

Nicolas Martz, Jean Christophe Faivre, Guillaume Beldjoudi, Antoine Arnaud, Jérôme Chamois, Stéphane Supiot, Maximilien Rogé, Sébastien Thureau.

We present the updated recommendations of the Société française de radiothérapie oncologique (the French society for radiation oncology) regarding the indications and technical modalities of radiotherapy for bone metastases. This treatment is commonly used in the management of patients with cancer. In most cases, it involves relatively simple radiotherapy technique with proven efficacy in reducing pain or managing spinal cord compression. More complex treatments using stereotactic conditions can be proposed for patients with painful bone metastases, oligometastatic disease, or in case of reirradiation. In this context, increased vigilance must be given to the risks of spinal cord toxicity.

Keywords: Bone metastases; Clinical practice guidelines; Métastases osseuses; Radiotherapy; Radiothérapie; Recommandations; SBRT; SFRO; Société française de radiothérapie oncologique; Stéréotaxie

DOI: https://doi.org/10.1016/j.canrad.2025.104769

Radiother Oncol. 2025 Dec 02. pii: S0167-8140(25)05308-3. [Epub ahead of print] 111304

ESTRO-ISRS clinical practice recommendations for re-irradiation of spinal mestastases with Stereotactic body radiotherapy: delphi consensus supported by a systematic review and meta-analysis.

Filippo Alongi, Francesco Cuccia, Rupesh Kotecha, Marina Campione, Alexander V Louie, Lijun Ma, Giuseppe Minniti, Alison C Tree, Max Dahele, Simon Lo, Per Munck Af Rosenschold, John H Suh, Maximilian Niyazi, Jason Sheehan, Matthias Guckenberger, Arjun Sahgal.

BACKGROUND: Stereotactic body radiotherapy (SBRT) is an established treatment for previously unirradiated spinal metastases; however, the literature is limited with respect to SBRT as a re-irradiation salvage therapy. We performed a systematic review and meta-analysis as basis for joint ESTRO-ISRS clinical practice recommendations of salvage SBRT for spinal metastases.
METHODS: A systematic review and meta-analysis were performed using PRISMA methodology, including publications from January 2006 to September 2024, reporting on the clinical outcomes of ≥ 5 patients treated with spine SBRT re-irradiation (≥5 Gy per fraction) for vertebral metastases. These data served as basis for joint ESTRO-ISRS clinical practice recommendations.
RESULTS: After the initial article screen, 20 studies (5 prospective, 15 retrospective) met the inclusion criteria for analysis. A total of 1538 spine metastases were treated in 1284 patients. The median re-irradiation dose was 24 Gy in 2 fractions (range: 16-30 Gy in 1-5 fractions) after a median 30 Gy in 10 fractions of prior conventional radiotherapy. Vertebral compression fracture, nerve root damage, and myelopathy events were observed in a pooled proportion of 5.0 %, 5.6 %, and 1.7 %, respectively. With a median follow-up of 12 months, the pooled 1- and 2-year LC rates were 81 % (95 % CI: 77-86 %) and 70 % (95 % CI: 61-79 %), respectively. Despite the low level of evidence, a consensus was reached after the first round of voting for 11 practice recommendations, suggesting a substantial level of agreement among the experts.
CONCLUSIONS: Re-irradiation with SBRT for spine metastases following prior conventional radiation or SBRT was efficacious, safe, and is a recommended treatment option in appropriately selected patients. Joint practice recommendations are provided on behalf of ESTRO and ISRS to guide clinical practice.

Keywords: External beam radiotherapy; Guidelines; Re-irradiation; Spinal metastases; Stereotactic Body Radiotherapy

DOI: https://doi.org/10.1016/j.radonc.2025.111304

J Bone Oncol. 2025 Dec;55 100727

Bone metastasis in colorectal cancer: Pathophysiology, prognostic factors, survival outcomes, and treatment strategies - A comprehensive review.

Lea Hatoum, Rita El Murr, Ahmad Assi, Rami Mohanna, Amer Sebaaly, Hampig-Raphaël Kourie.

Background: Colorectal cancer ranks as the third most prevalent cancer globally, with over 1.9 million new cases and 930,000 deaths in 2020. While the liver and lungs are the most common site of colorectal cancer metastases, bone metastasis is relatively rare but clinically significant. The rarity of bone metastasis in colorectal cancer, early diagnosis challenges, and the poorly understood mechanisms underlying bone metastasis have resulted in lesser research compared to other metastatic sites of colorectal cancer.
Objective: The goal of this review is to summarize pathophysiology, clinical presentation, risk and prognostic factors, survival outcomes, and treatment options for bone metastasis in colorectal cancer. Results: Bone metastasis occurred in 6 to 10 % of colorectal cancer patients, with the spine and pelvis being the most common sites. Bone metastasis from colorectal cancer may result from hematogenous dissemination and retrograde venous flow through Batson's plexus. Early diagnosis can be challenging, and Positron Emission Tomography / Computed Tomography (PET/CT) provided the best accuracy for diagnosing bone metastasis in colorectal cancer. Isolated bone metastasis, low neutrophil-to-lymphocyte ratio (NLR) (high NLR with HR: 1.54), low alkaline phosphatase levels, N0 stage colorectal cancer were associated with a better prognosis and survival. High carcinoembryonic antigen (OR: 2.368, HR: 3.300), alkaline phosphatase (OR: 6.89, HR: 2.12), and CA 19-9 levels (HR: 1.5), Lactate dehydrogenase (HR: 1.961), perineural invasion (HR: 3.457), right sided location (HR: 1.84), multiples bone metastasis sites (HR: 1.452), hypercalcemia (HR: 3.75), pathologic fracture (HR:1.91) and more than two extra-bone metastatic organs (HR: 2.357) were linked to worse prognosis. The therapeutic approach for colorectal cancer patients with bone metastasis consists of a multidisciplinary strategy including systemic chemotherapy, palliative surgery, radiotherapy and bisphosphonate.
Conclusion: Early diagnosis and management of bone metastasis in colorectal cancer patients is essential to improve quality of life and survival. Further research is needed to identify methods for early detection and develop tailored treatment strategies.

Keywords: Bone metastasis; Colorectal cancer; Prognostic factors

DOI: https://doi.org/10.1016/j.jbo.2025.100727